Ascendis Pharma A/S Q3 2018 Earnings Call Transcript - Thomson StreetEvents

Ascendis Pharma A/S Q3 2018 Earnings Call Transcript

Ascendis Pharma A/S Q3 2018 Earnings Call Transcript - Thomson StreetEvents
Ascendis Pharma A/S Q3 2018 Earnings Call Transcript
Published Nov 28, 2018
Published Nov 28, 2018
Price US$ 54.00  |  Buy this Report Now

About This Report

  
Abstract:

Edited Transcript of ASND.OQ earnings conference call or presentation 28-Nov-18 9:30pm GMT

  
Report Type:

Transcript

Source:
Thomson StreetEvents
Company:
Ascendis Pharma A/S
Ticker
ASND.OQ
Time
9:30pm GMT
Format:
PDF Adobe Acrobat
Buy Now

The following is excerpted from the question-and-answer section of the transcript.

(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)

Question: Michelle Lim Gilson - Canaccord Genuity Limited, Research Division - Analyst : I was just wondering, can you talk a little bit about the path forward for TransCon CNP? And what is the age range of patients that you plan to enroll in your Phase II study? And then you talk a lot about correcting comorbidities. And can you talk a little bit about how young you think that patients may be treated in order to correct for those comorbidities? And then I have a follow-up as well.

Question: Michelle Lim Gilson - Canaccord Genuity Limited, Research Division - Analyst : Okay. And then when you think about dose in that Phase II, when you're choosing a Phase II dose range or dose, are you looking at trends that you see in nature with CNP within the population or data from others in the space or what you're seeing in animals? And then are you thinking about it, about looking at it based on concentration or titrating that dose?

Question: Jessica Macomber Fye - JP Morgan Chase & Co, Research Division - Analyst : I wanted to follow-up on one of the earlier questions. I'm curious as you think about discussing Phase II with the FDA for TransCon CNP, what you want to measure and what you might kind of ask the FDA for feedback on in terms of what you measure in that study, I guess, outside of just growth?

Question: Jessica Macomber Fye - JP Morgan Chase & Co, Research Division - Analyst : Okay. And I guess I'm just kind of asking because if you're-- if you think titration to maybe a given free CNP level may be how the product is used, I'm curious what you might measure to establish an association that different levels have different effects on whatever those metrics are.

Question: Jessica Macomber Fye - JP Morgan Chase & Co, Research Division - Analyst : Okay. And I'm trying to re-ask my question from last quarter. Can you just provide the latest status of where you stand on manufacturing for TransCon GH and those validation batches? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. NOVEMBER 28, 2018 / 9:30PM, ASND.OQ - Q3 2018 Ascendis Pharma A/S Earnings Call

Table Of Contents

Ascendis Pharma A/S at Morgan Stanley Global Healthcare Conference (Virtual) Transcript – 2020-09-17 – US$ 54.00 – Edited Transcript of ASND.OQ presentation 17-Sep-20 7:30pm GMT

Ascendis Pharma A/S Q2 2020 Earnings Call Transcript – 2020-08-27 – US$ 54.00 – Edited Transcript of ASND.OQ earnings conference call or presentation 27-Aug-20 8:30pm GMT

Ascendis Pharma A/S at Canaccord Genuity Growth Conference (Virtual) Transcript – 2020-08-12 – US$ 54.00 – Edited Transcript of ASND.OQ presentation 12-Aug-20 5:30pm GMT

Ascendis Pharma A/S at Wedbush PacGrow Healthcare Virtual Conference Transcript – 2020-08-11 – US$ 54.00 – Edited Transcript of ASND.OQ presentation 11-Aug-20 6:20pm GMT

Ascendis Pharma A/S Q1 2020 Earnings Call Transcript – 2020-05-19 – US$ 54.00 – Edited Transcript of ASND.OQ earnings conference call or presentation 19-May-20 8:30pm GMT

More from Thomson StreetEvents

Thomson StreetEvents—Thomson StreetEvents is a leading provider of Web-based solutions for the investment community, offering services that transform the way companies communicate and meet disclosure requirements while assisting investors in managing and leveraging this information. Thomson StreetEvents service offers institutional investors a one-stop solution for managing corporate disclosure information by aggregating conference calls, webcasts, transcripts, call summaries, and other financial information into a time-saving, efficiency tool.
Purchase Thomson StreetEvents' Transcripts (verbatim reports) and Briefs (call summaries) of earnings, guidance, M&A and other corporate calls directly through Alacra. Discounted prices apply to reports produced over two weeks ago.

About the Author


Cite this Report

  
MLA:
Thomson StreetEvents. "Ascendis Pharma A/S Q3 2018 Earnings Call Transcript" Nov 28, 2018. Alacra Store. May 05, 2025. <http://www.alacrastore.com/thomson-streetevents-transcripts/Q3-2018-Ascendis-Pharma-A-S-Earnings-Call-T12196206>
  
APA:
Thomson StreetEvents. (2018). Ascendis Pharma A/S Q3 2018 Earnings Call Transcript Nov 28, 2018. New York, NY: Alacra Store. Retrieved May 05, 2025 from <http://www.alacrastore.com/thomson-streetevents-transcripts/Q3-2018-Ascendis-Pharma-A-S-Earnings-Call-T12196206>
  
US$ 54.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Credit Research from one place.